Summary
Pfizer Inc. (PFE) filed an 8-K on December 16, 2010, detailing significant leadership changes and compensation adjustments. The report confirms Ian C. Read's transition to President and CEO, effective January 1, 2011, accompanied by a substantial increase in his base salary and target annual incentive. Additionally, Frank A. D’Amelio, CFO, received an increase in his base salary and target annual incentive, reflecting his expanded responsibilities. Beyond executive compensation, the filing announces the appointment of George A. Lorch as the non-executive Chairman of the Board, a move designed to streamline board leadership. These changes signal a new phase for Pfizer's executive team, with direct implications for their strategic direction and financial stewardship. Investors should monitor how these leadership transitions and associated compensation structures influence future performance and corporate strategy.
Key Highlights
- 1Ian C. Read appointed President and Chief Executive Officer (CEO) effective January 1, 2011.
- 2Ian C. Read's annual base salary increased to $1,700,000 from $1,210,000.
- 3Ian C. Read's target annual incentive for 2011 increased to $2,587,500, representing 150% of his salary midpoint.
- 4Frank A. D’Amelio, CFO, received an increase in his annual base salary to $1,200,000 from $1,100,000.
- 5Frank A. D’Amelio's target annual incentive for 2011 increased to $1,125,000, representing 100% of his salary midpoint.
- 6George A. Lorch elected as non-executive Chairman of the Board, effective December 13, 2010.
- 7James M. Kilts appointed as Chair of the Compensation Committee.